be examining the role of basolateral membrane transporters, such as the basolateral sodium-bicarbonate cotransporter NBC1, which is not normally directly accessible in vivo (2, 11) . One of the major drawbacks of the in vitro approach, however, is that the only accepted physiological stimulus for bicarbonate secretion, namely exposure of the luminal surface to 1-6.3 mM HCl, cannot be used due to the high probability of producing mucosal damage (20) . Furthermore, the low pH used to stimulate secretion might alter the properties of inhibitors and other interventions designed to work optimally at neutral pH. Thus surrogate secretagogues, such as cyclic nucleotides and hormones have been used under the likely assumption that these compounds are involved in the secretory response to luminal acid. Indeed, variations in response of tissues to different secretagogues have been used to highlight possible differences between normal and disease-bearing tissues (14) . Nevertheless, it is not known whether bicarbonate secretion to these surrogate stimuli is a physiological or a pharmacological phenomenon.
In response to this question, we have compared the mucosal secretory responses to one secretagogue, PGE 2 , compared with the response to physiological acid challenge. PGE 2 was chosen due to its universal acceptance as an important component of the mucosal response to luminal acid recently compounded by powerful evidence obtained from the study of transgenic mice (18) . We hypothesized that the appropriate dose of exogenous PGE 2 would likely mimic the physiological mucosal response to luminal acid without producing additional pharmacological effects. We thus compared the effects of several known inhibitors on PGE 2 and acid-related DBS. We found that a low dose of PGE 2 closely mimicked the secretory effect of prior acid exposure and thus could be used in vitro to simulate the mucosal secretory response to luminal acid.
MATERIALS AND METHODS

Animals and Chemicals
Male C57BL/6 mice (Harlan Sprague Dawley, Hercules, CA) were maintained with free access to food and tap water up to 1 h before the experiment when food was removed. All studies were approved by the Animal Use Committee of the Greater Los Angeles Veterans Administration Healthcare System. DIDS, 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB), methazolamide indomethacin, HEPES, and other chemicals were obtained from Sigma (St. Louis, MO). PGE 2 was obtained from Oxford Biochemical (Oxford, MI). HEPES-saline solution contained 135 mM NaCl and 20 mM HEPES at pH 7.0. For acid perfusion, isotonic NaCl was adjusted to pH 4.5, 3.5, and 2.2 with HCl and adjusted to isotonicity (300 mosM) by reducing the NaCl concentration accordingly. Each solution was prewarmed to 37°C with temperature maintained by a heating pad during the experiment. PGE 2 was dissolved with absolute ethanol to make a concentrated stock solution. NPPB, methazolamide, and indomethacin were dissolved with DMSO, and DIDS was dissolved with distilled water to make a concentrated stock solution. PGE 2 was diluted with pH 7.0 saline to each concentration just before the stimulation.
Measurement of Duodenal Loop Bicarbonate Secretion
Preparation of the duodenal loop. Duodenal loops were prepared and perfused to measure duodenal HCO 3 Ϫ secretion modified from the similar system as described previously in rats (1, 17) . In urethaneanesthetized mice (1.0 g/kg), the stomach and duodenum were exposed, and the forestomach wall was incised by using a miniature electrocautery. A polyethylene tube was inserted through the incision to the pyloric ring where it was secured with a nylon ligature. The distal duodenum was ligated proximal to the ligament of Treitz and was then incised through which another polyethylene tube was inserted and sutured into place. To prevent contamination of the perfusate with bile-pancreatic juice, the pancreaticobiliary duct was ligated just proximal to its insertion into the duodenal wall. The resultant closed proximal duodenal loop was perfused with prewarmed saline using a peristaltic pump at 0.2 ml/min.
Bicarbonate secretion measurement by pH-stat. Input (perfusate) and effluent of the duodenal loop were circulated through a reservoir and bubbled with 100% O 2. Perfusate pH was kept at pH 7.0 with a pH-Stat (models PHM290 and ABU901; Radiometer Analytical, Lyon, France). For pH-stat measurements, the amount of 10 mM HCl added to maintain constant pH of the perfusate was considered equivalent to duodenal HCO 3 Ϫ secretion. For duodenal HCO 3 Ϫ measurement, a 30-min stabilization with pH 7.0 saline (t ϭ Ϫ35 to Ϫ5) was followed by baseline measurements with pH 7.0 saline (t ϭ Ϫ5-25). To examine the acid-induced bicarbonate secretion, acid solution was perfused with a Harvard infusion pump at 0.2 ml/min for 10 min (t ϭ 25-35). To examine PGE2-induced bicarbonate secretion, PGE 2 (1-100 g/ml) was perfused at 0.2 ml/min for 10 min (t ϭ 25-35). The duodenal loop solution was returned to O 2 gas-bubbled pH 7.0 saline for 60 min after being gently flushed (t ϭ 35-95). In some experiments, indomethacin (5 mg/kg) was administered subcutaneously 1 h before the experiment.
CO2 measurement. To confirm that the titratable base secretion (acid disappearance) measured by the pH-stat technique reflected true HCO 3 Ϫ secretion (2), we also measured total dissolved CO2 concentration ([CO 2]t) in some but not all conditions. [CO2]t of the duodenal effluent was measured by a CO 2 electrode gas-sensing electrode (model 950200; Thermo Orion) connected to a pH meter [model PHM 62; Radiometer, Copenhagen, Denmark] (1). Duodenal loops were prepared and perfused with 20 mM HEPES containing saline (pH 7.0) at a rate 0.2 ml/min as described in Animals and Chemicals. Effluent was collected every 10 min; 0.2 ml of 1 M citrate buffer (pH 4.5) was then added to the sample solution (2 ml) to convert free HCO3 to CO2, followed by measurement of electrode potential (mV) with the CO 2 electrode. [CO2]t was calculated according to a calibration curve using freshly prepared 0.1, 1, and 10 mM NaHCO 3 solutions as standards, which generate 0.1, 1, and 10 mM [CO 2]t, respectively (1). For duodenal [CO 2]t measurement, a 30-min stabilization with pH 7.0 saline (t ϭ Ϫ30 -0) was followed by baseline measurements with pH 7.0 saline (t ϭ 0 -30). To examine the acid-induced bicarbonate secretion, acid solution was perfused with a Harvard infusion pump at 0.2 ml/min for 10 min (t ϭ 30 -40). PGE 2 (1-100 g/ml) was perfused at 0.2 ml/min for 10 min (t ϭ 30 -40). The duodenal loop solution was returned to pH 7.0 saline for 60 min after being gently flushed (t ϭ 40 -100).
In some cases, the anion channel inhibitor NPPB (0.2 mM), the anion transport inhibitor DIDS (0.5 or 1 mM), or the permeant carbonic anhydrase inhibitor methazolamide (0.1 or 1 mM) was added to the duodenal perfusate.
Statistics
All data from six rats in each group are expressed as means Ϯ SE. Comparisons between groups were made by one-way ANOVA followed by Fisher's least significant difference test.
RESULTS
Effect of Methazolamide, DIDS, and NPPB on Acid-Induced DBS
Initial experiments were designed to examine DBS in response to a prior pulse of acid in the mouse, with and without the presence of known transport inhibitors. Consistent with prior studies, DBS significantly increased after a 10-min exposure to pH 2.2 and 3.5 solutions (peak DBS: 0.053 Ϯ 0.005 and 0.0044 Ϯ 0.002 mol⅐min Ϫ1 ⅐cm Ϫ1 , respectively), but DBS did not increase after exposure to a pH 4.5 perfusate (peak DBS: 0.030 Ϯ 0.001 mol⅐min Ϫ1 ⅐cm Ϫ1 ; Fig. 1 ). We then confirmed the effect of the anion transport inhibitor DIDS and the anion channel inhibitor NPPB on DBS. Both DIDS and NPPB inhibited acid-increased DBS ( Fig. 2A) , confirming the importance of DIDS-and NPPB-sensitive transport processes in DBS. We then tested the effect of the nonselective cyclooxygenase inhibitor indomethacin on DBS to examine the effects of endogenously generated prostaglandins on DBS. Pretreatment with indomethacin (5 mg/kg sc) inhibited acidinduced DBS increase as measured by back-titration (Fig. 2B) . We then examined the effects of methazolamide and DIDS on Fig. 1 . pH-dependent effect of acid on bicarbonate secretion by the pH-stat method. Titratable alkalinity (bicarbonate secretion) was measured by the pH-stat method in duodenal loop perfusion experiments. Acid pH-dependently increased duodenal bicarbonate secretion (DBS) after acid exposure. All data are expressed as means Ϯ SE from 6 -8 mice. *P Ͻ 0.05 vs. pH 7.0 saline perfusion. acid-induced DBS by measurement of [CO 2 ] t . DBS increased after pH 2.2 acid exposure and was abolished by DIDS and by methazolamide (Fig. 3) .
Effect of Methazolamide DIDS and NPPB on Basal DBS
We then tested the effects of the inhibitors on basal (nonstimulated) DBS. NPPB (0.2 mM) had no effect on basal DBS. Methazolamide (1 mM) also did not alter DBS, whereas DIDS (0.5 mM) slightly reduced baseline DBS after prolonged perfusion (DIDS: 0.060 Ϯ 0.001 mol⅐min Ϫ1 ⅐cm Ϫ1 , saline: 0.074 Ϯ 0.005 mol⅐min Ϫ1 ⅐cm
Ϫ1
; Fig. 4 ).
Effect of Methazolamide, DIDS, and NPPB on PGE2-Induced DBS
We then assessed the effects of PGE 2 perfusion on DBS compared with acid perfusion. Figure 5 depicts the effects of three concentrations of PGE 2 on DBS as measured by [CO 2 ] t . PGE 2 dose-dependently increased peak DBS (PGE 2 : 100 g/ ml, 0.126 Ϯ 0.008; 10 g/ml, 0.101 Ϯ 0.005; and 1 g/ml, 0.093 Ϯ 0.003 mol⅐min Ϫ1 ⅐cm
Ϫ1
). By using similar conditions, we then tested the effects of methazolamide on PGE 2 -stimulated DBS. It is interesting that 0.1 mM methazolamide inhibited low-dose PGE 2 -induced DBS, but neither concentration of methazolamide inhibited high-dose PGE 2 -induced DBS (Fig. 6 ). Figure 7 depicts the effect of DIDS on PGE 2 -induced DBS by total CO 2 measurement. DIDS (0.5 mM) inhibited low-dose PGE 2 -induced DBS, but DIDS (0.5, 1 mM) only partially attenuated high-dose PGE 2 -induced DBS. There was thus a difference between high-dose and low-dose PGE 2 -induced DBS, suggesting different secretory pathways. Figure  8 depicts the effect of three concentrations of PGE 2 on DBS, as measured by back-titration. PGE 2 dose-dependently increased Fig. 2 . Effect of DIDS 5-nitro-2-2(3-phenylpropylamino)benzoic acid (NPPB) and indomethacin on acid-induced bicarbonate secretion by the pH-stat method. A: both DIDS and NPPB inhibit the increased bicarbonate secretion after acid exposure. All data are expressed as means Ϯ SE from 6 mice. *P Ͻ 0.05 vs. pH 2.2 saline perfusion. B: pretreatment with indomethacin (5 mg/kg sc) inhibited pH 2.2 acid-induced bicarbonate secretion. All data are expressed as means Ϯ SE from 6 mice. *P Ͻ 0.05 vs. pH 2.2 saline perfusion. Fig. 3 . Effects of methazolamide and DIDS on acid-induced bicarbonate secretion by the CO2-sensitive electrode method. DBS increased after pH 2.2 acid exposure also by total CO2 measurement. Both DIDS and methazolamide inhibited acid-induced DBS total CO2 concentration ([CO2]t) increase but with no synergistic effect between DIDS and methazolamide. All data are expressed as means Ϯ SE from 6 -7 mice. *P Ͻ 0.05 vs. pH 2.2 saline perfusion.
peak DBS (PGE 2 : 100 g/ml, 0.058 Ϯ 0.004; 10 g/ml, 0.052 Ϯ 0.002; 1 g/ml, 0.048 Ϯ 0.003 mol⅐min Ϫ1 ⅐cm Ϫ1 ) similar to but with a longer duration than PGE 2 -induced increased [CO 2 ] t . We then examined the effect of NPPB on PGE 2 -induced DBS by back-titration. NPPB (0.2 mM) inhibited low-dose PGE 2 -induced DBS, whereas NPPB did not abolish high-dose PGE 2 -induced DBS (Fig. 9) , suggesting that anion channels are involved in low-dose PGE 2 -induced DBS. Pretreatment with indomethacin (5 mg/kg sc) did not inhibit low-dose as well as high-dose PGE 2 -induced DBS increase as measured by [CO 2 ] t (Fig. 10) .
DISCUSSION
We demonstrated that acid-stimulated DBS in C57BL/6 mice is inhibited as it is in rats by NPPB, DIDS, and metha- 5 . Effect of PGE2 on bicarbonate secretion by the CO2-sensitive electrode method. PGE2 dose-dependently increased DBS after PGE2 exposure for 10 min (1-100 g/ml) by total CO2 measurement. All data are expressed as means Ϯ SE from 6 -8 mice. Fig. 6 . Effects of methazolamide on high-dose and low-dose PGE2-induced bicarbonate secretion by the CO2-sensitive electrode method. A: methazolamide (0.1 mM) inhibited low-dose PGE2 (1 g/ml)-induced DBS. B: methazolamide (0.1 mM, 1 mM) did not alter high-dose PGE2 (100 g/ml)-induced DBS. All data are expressed as means Ϯ SE from 6 mice. *P Ͻ 0.05 vs. PGE2 perfusion group.
zolamide. The same compounds inhibited DBS in response to 1 g/ml-perfused PGE 2 but not in response to 100 g/mlperfused PGE 2 . On the basis of these data, we conclude that 1 g/ml PGE 2 mimics the physiological response to duodenal acid perfusion.
The duodenal bicarbonate secretory response to luminal acid perfusion is thought to be the primary means by which duodenal injury due to luminal acid is prevented (6) . Luminal acid is thought to be the principal endogenous stimulus of DBS. Although the entire secretory mechanism consisting of afferent acid sensors, neural circuits, cellular transduction, and plasma membrane ion transporters is only beginning to be fully understood, the broad pathways that regulate DBS are well characterized. The main classes of secretory signals consist of cAMP, cGMP, and prostaglandin-related signals. The necessity of studying acid-induced DBS in an in vivo system has somewhat limited detailed knowledge of the cell biology of acid-related secretion, although several recent studies have indicated that this response involves prostaglandin generation in a step that is likely close to the final secretory pathway, in that cyclooxygenase inhibition suppresses DBS in response to acid and to a variety of stimuli (10, 16, 18) . Moreover, mice lacking the gene for the prostaglandin EP 3 receptor have defective DBS in response to duodenal acid perfusion (18) . Furthermore, luminal acid perfusion releases mucosal prostaglandins (16) . We therefore chose PGE 2 as a logical secretagogue to mimic the physiological duodenal secretory acid response.
The mechanism by which HCO 3 Ϫ is secreted by the duodenum remains controversial. There is consensus that HCO 3 Ϫ is taken into the cell by the basolateral NBC1 and as CO 2 , and that the main secretory pathways are CFTR and an anion exchanger on the enterocyte apical membrane. Furthermore, basal and carbonic anhydrase-inhibitable secretion is mostly electroneutral, whereas cAMP-stimulated secretion is mostly electrogenic, and is thought to result from upregulation of NBC1 function (3, 11) . Because measurement of short-circuit current in vivo is not possible, we would prefer not to speculate on the mechanism of secretion elicited by low and high-dose PGE 2 . The secretory response to PGE 2 and acid perfusion is generally slow to develop and is prolonged. One interesting observation is that although acid-induced secretion as measured either by [CO 2 ] t or back-titration is prolonged, secretion in response to PGE 2 develops and falls more quickly when measured by [CO 2 ] t compared with back-titration. This suggests that the long recovery to baseline rates of secretion reflects probable non-HCO 3 Ϫ alkaline secretion. dose-dependently increased DBS after PGE2 exposure for 10 min (1-100 g/ml) by pH-stat back-titration. All data are expressed as means Ϯ SE from 6 -8 mice.
Since the discovery of the intestinal prosecretory effects of the E-type prostaglandins in the 1970s, and the development of stable prostaglandin analogs such as 16 -16-dimethyl PGE 2 , these compounds have been the preferred secretagogues for duodenal bicarbonate. Despite the extensive use of prostaglandins to augment DBS in vivo, there have been few doseresponse studies of its action. In rabbit duodenum, Granstam et al. (8) (19) and 10 g/ml (26 M) in rats (17) . A dose of 10 M (3.8 g/ml) in rats also is commonly used (21) . Thus the dose employed by us (1-100 g/ml or 0.38 -38 M) ranges from ϳ2 to 200% of the consensus mammalian ED 50 for this compound of ϳ20 M.
Secretagogues used for augmentation of HCO 3 Ϫ secretion in vitro include cAMP, prostaglandins, vasoactive intestinal peptide, carbachol, and cGMP agonists such as heat-stable Escherichia coli toxin (STa) with the most commonly used being cAMP analogs (3, 15a, 14, 22) . Although all of these compounds can produce a robust secretory response, few studies have addressed the comparability of this response to the phys- iological effect of a prepulse of luminal acid measured in vivo. Although the use of inhibitors of limited specificity could be considered somewhat crude, their effects are strikingly dependent on the mode of HCO 3 Ϫ stimulation, uncovering similarities and differences with acid-induced secretion in vivo. The same is true in the case of dysfunction of a key element of the secretory pathway, the apical membrane CFTR. For example, in the presence of a dysfunctional, mutant CFTR, or in CFTR knockout mice, basal HCO 3 Ϫ secretion is reduced, and the response to acid is abolished (9) . In an in vitro system using tissue obtained from cystic fibrosis patients carrying the ⌬F508 mutation, this pattern of response was observed with cAMP but not with STa or with carbachol, suggesting that the cAMP response more closely resembled the acid response (14) . These studies confirm that the presumed secretory mechanism is dependent on the stimulus provided.
To help further establish specificity, the inhibitors NPPB, DIDS, and methazolamide were used, due to their well-known inhibition of DBS. NPPB, an anion channel inhibitor, is believed to inhibit the CFTR anion channel, which is functionally closely tied to bicarbonate secretion. The inhibitory mechanism of DIDS, a relatively nonspecific stilbene anion transport protein inhibitor, on bicarbonate secretion is less agreed on but may reflect inhibition of either the apical membrane anion exchanger, whose identity is at present controversial (15a), and/or the basolateral membrane sodium-bicarbonate cotransporter NBC1 (3, 7, 11) . In vivo, DIDS and NPPB abolish the HCO 3 Ϫ secretory response to luminal acid (2) . Similar to our results obtained in vivo, luminally applied DIDS in vitro in rabbit duodenum abolished the HCO 3 Ϫ secretory response to 100 M (38 g/ml) PGE 2 but not to cAMP (22) , and basolaterally applied DIDS abolished the secretory response to 10 g/ml PGE 2 in bullfrog duodenum (7) . Other groups have also confirmed that the secretory response to cAMP measured in vitro is not inhibited by DIDS alone (3, 15a) . This lack of DIDS sensitivity to cAMP-induced secretion is hence unlike the secretory response to acid observed in vivo. This observation supports the hypothesis that the response to PGE 2 in vitro and in vivo, which is DIDS inhibitable, more closely resembles the physiological acid-induced secretory response than does the response in vitro to cAMP. Methazolamide, or the related compound acetazolamide, inhibitors of carbonic anhydrase, also inhibits basal and stimulated bicarbonate secretion, presumably by inhibiting hydration of intracellular CO 2 . Although methazolamide given subcutaneously did not inhibit secretion stimulated by 10 g/ml PGE 2 in rats (17) , when used in vitro it inhibited electroneutral secretion in mouse duodenum (3) and basal but not cAMP-stimulated secretion in rabbit duodenum (11) . Indomethacin, the nonselective cyclooxygenase inhibitor, strongly inhibited acid-induced DBS but did not affect PGE 2 -induced secretion in rat duodenum in vivo in our study or as observed by other groups (10, 19) consistent with its mechanism of inhibiting endogenous prostaglandin production but not the effects of exogenous prostaglandin administration. By using an array of inhibitors, each with an effect on a different component of the bicarbonate secretory pathway, we created a pattern that identified the secretory pathway augmented by luminal acid exposure. More detailed studies have indicated that the DIDS-resistant, cAMP-elicited pathway occurs by a different mechanism than does basal secretion and may reflect secretion under conditions such as inflammation and not the more common response to luminal acid (15a) .
A limitation of this study is that the intended vitro preparation may differ in sensitivity from the in vivo preparations used. Although it is not possible to use concentrated acid with in vitro preparations due to the aforementioned high likelihood of damaging the mucosa (20) and hence make direct comparisons, the limited published data (22) from which an assessment can be made suggests that comparable PGE 2 concentrations can be used in vivo.
In summary, we found that a dose of prostaglandin lower than is usually used in vitro augmented DBS measured in vivo with similar magnitude and inhibitor profile as did a prepulse of luminal acid. In in vitro studies of DBS, low doses of prostaglandin can be used as a surrogate for luminal acid exposure to help better understand the apical and basolateral mechanisms involved with bicarbonate secretion. With more understanding of the mechanism of duodenal HCO 3 Ϫ secretion, other secretagogues such as melatonin (15) might also be used in vitro to simulate the duodenal secretory acid response.
